DICER1 and metastatic neoplasm: NRAS mutations were significantly more frequent in metastatic tumors (42.2%) compared to primary tumors (29.2%), while DICER1 mutations were more common in primary tumors (16.13% vs. 1.96% in metastases, p < 0.02).